search
Back to results

Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses (LevoHydroxy)

Primary Purpose

Chronic Urticaria

Status
Completed
Phase
Phase 4
Locations
Bulgaria
Study Type
Interventional
Intervention
Levocetirizine
Levocetirizine plus Hydroxyzine
Sponsored by
Association Asthma, Bulgaria
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Urticaria focused on measuring Chronic urticaria, Urticaria, Antihistamine

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 24 randomized patients of either sex,
  • ≥18 years of age.
  • Included patients should have at least a 6-week documented history of urticaria with intake of 15-30 mg Prednisolon.

Exclusion Criteria:

  • Patients with physically induced urticarias;
  • pregnancy and lactation;
  • any chronic disease requiring daily other drug treatment including, antihypertensives, antipsychotics and antidepressants;
  • other skin disease

Sites / Locations

  • Medical University Sofia, Department of Allergology

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Levocetirizine

Levocetirizine plus Hydroxyzine

Arm Description

24 patients will received 20 mg Levocetirizine daily

24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days

Outcomes

Primary Outcome Measures

Urticaria specific quality of life
The primary objective of the study is to compare the effect on urticaria specific quality of life of two regimens: levocetirizine 20 mg per day (4x1 tablets) vs. levocetirizine 15 mg (3x1 tablets) + hydroxyzine 50 mg (2 tablets) before night time sleep.

Secondary Outcome Measures

Effect of the two regimens on urticaria symptoms
To compare the effect of the two regimens on urticaria symptoms (number of wheals, pruritus severity
Effect on night time sleep
To compare the effect of the two regimens on the quality of night time sleep
Effect on day time somnolence
To compare the effect of the two regimens on the day time somnolence.
The effect on blood eosinophil numbers, Na+, K+, ALAT, ASAT, ECG
To document the effect of treatment with higher doses of levocetirizine or hydroxyzine on blood eosinophil numbers, Na+(sodium ion), K+(potassium ion), ALAT (Alanine transaminase), AST (Aspartate transaminase), ECG (Electrocardiogram)
To assess adverse events
To investigate safety by assessing the nature, incidence and severity of adverse events within the treatment groups

Full Information

First Posted
November 30, 2010
Last Updated
July 15, 2013
Sponsor
Association Asthma, Bulgaria
Collaborators
UCB Pharma
search

1. Study Identification

Unique Protocol Identification Number
NCT01250652
Brief Title
Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses
Acronym
LevoHydroxy
Official Title
Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
March 2011 (undefined)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
March 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Association Asthma, Bulgaria
Collaborators
UCB Pharma

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Allen Kaplan is a prominent American allergist with the reputation of leader in the field of chronic urticaria. He advocates treatment with first generation hydroxyzine, which he considers at least as effective as modern second generation H1-blockers in suppressing the symptoms of difficult-to-treat / systemic-steroid-dependant cases of chronic urticaria. He further speculates that hydroxyzine may have the advantage to better suppress itch and improve nighttime sleep. This has prompted many practitioners around the world to believe that adding hydroxyzine to the treatment regimen at bed time at night may be beneficial to patients. At the same time European guidelines indicate modern second generation H1-blockers in higher than conventional doses as drugs of choice for such cases. However, there is no evidence from clinical trials addressing this controversy. The investigators' previous studies suggest that levocetirizine at quadruple doses may be beneficial in difficult to treat urticaria by reducing lesions and itch, improving quality of life and night time sleep, while not causing day time somnolence. First generation H1-receptor antagonists and hydroxyzine among them are known to penetrate the blood / brain barrier and to cause sedation. The question stays whether this sedation is beneficial to the subjects with chronic urticaria at night, whether it has any hang-over unwanted effects the following day and whether this has any influence on the overall urticaria-specific quality of life.
Detailed Description
Study design: The study will involve two distinct parts (flow chart): In-hospital assessment of effectiveness and tolerability of 10 & 20 mg levocetirizine vs. 100 & 200 mg hydroxyzine in subjects to be weaned off corticosteroid treatment. Subsequent ambulatory treatment of the same patients with 20 mg levocetirizine alone and 15 mg levocetirizine + 50 hydroxyzine at night Protocol description Patients with chronic urticaria treated with systemic steroids are traditionally admitted to the Clinic of Allergy and Asthma in Sofia to try to wean them off this class of drugs. Hospitalized patients will be invited to take part in the study and will sign an informed consent. They will be assessed by standard questionnaire and by objective assessment of the urticarial lesions, QoLQ will be filled in, discomfort due to urticaria, day time somnolence and night time sleep quality will be assessed on a visual analogue scale. Systemic steroids will be withheld and patients would be given 10 mg levocetirizine on Days 1 & 2; after a new assessment of quality of night time sleep and day time somnolence, 100 mg hydroxyzine will be given on Days 3 & 4. The cycle will be repeated on Days 5 & 6 and Days 7 & 8 with 20 mg levocetirizine and 200 hydroxyzine respectively. At this point patients will be discharged and randomized to two treatment arms: levocetirizine 20 mg per day and levocetirizine 15 mg + hydroxyzine 50 mg as evening dose for 5 days. Diaries will be given to patients for assessment of daily SS, day time somnolence score, quality of night time sleep, facial tissue swelling, rescue medication with oral prednisolone, adverse events, intake of any other medications. After 5 days the patients from arm 1 and 2 will be crossed over to the alternative treatment. QoLQ questionnaire will be filled out at onset, at cross over (day 5) and at the end of the 10 day treatment period. On completion of the study subjects will be asked to state there preference for one treatment or the other.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Urticaria
Keywords
Chronic urticaria, Urticaria, Antihistamine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Levocetirizine
Arm Type
Active Comparator
Arm Description
24 patients will received 20 mg Levocetirizine daily
Arm Title
Levocetirizine plus Hydroxyzine
Arm Type
Experimental
Arm Description
24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
Intervention Type
Drug
Intervention Name(s)
Levocetirizine
Other Intervention Name(s)
Xyzal
Intervention Description
20 mg levocetirizine for 5 days
Intervention Type
Drug
Intervention Name(s)
Levocetirizine plus Hydroxyzine
Other Intervention Name(s)
Xyzal plus Atarax
Intervention Description
24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
Primary Outcome Measure Information:
Title
Urticaria specific quality of life
Description
The primary objective of the study is to compare the effect on urticaria specific quality of life of two regimens: levocetirizine 20 mg per day (4x1 tablets) vs. levocetirizine 15 mg (3x1 tablets) + hydroxyzine 50 mg (2 tablets) before night time sleep.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Effect of the two regimens on urticaria symptoms
Description
To compare the effect of the two regimens on urticaria symptoms (number of wheals, pruritus severity
Time Frame
1 year
Title
Effect on night time sleep
Description
To compare the effect of the two regimens on the quality of night time sleep
Time Frame
1 year
Title
Effect on day time somnolence
Description
To compare the effect of the two regimens on the day time somnolence.
Time Frame
1 year
Title
The effect on blood eosinophil numbers, Na+, K+, ALAT, ASAT, ECG
Description
To document the effect of treatment with higher doses of levocetirizine or hydroxyzine on blood eosinophil numbers, Na+(sodium ion), K+(potassium ion), ALAT (Alanine transaminase), AST (Aspartate transaminase), ECG (Electrocardiogram)
Time Frame
1 year
Title
To assess adverse events
Description
To investigate safety by assessing the nature, incidence and severity of adverse events within the treatment groups
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 24 randomized patients of either sex, ≥18 years of age. Included patients should have at least a 6-week documented history of urticaria with intake of 15-30 mg Prednisolon. Exclusion Criteria: Patients with physically induced urticarias; pregnancy and lactation; any chronic disease requiring daily other drug treatment including, antihypertensives, antipsychotics and antidepressants; other skin disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Todor A Popov, MD, PhD
Organizational Affiliation
Professor of Allergology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University Sofia, Department of Allergology
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria

12. IPD Sharing Statement

Citations:
PubMed Identifier
15356542
Citation
Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004 Sep;114(3):465-74; quiz 475. doi: 10.1016/j.jaci.2004.02.049.
Results Reference
background
PubMed Identifier
19081615
Citation
Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol. 2009 Mar;123(3):713-7. doi: 10.1016/j.jaci.2008.10.050. Epub 2008 Dec 10. No abstract available.
Results Reference
background
PubMed Identifier
20226302
Citation
Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, Dimitrov V, Church MK. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010 Mar;125(3):676-82. doi: 10.1016/j.jaci.2009.11.047.
Results Reference
background

Learn more about this trial

Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses

We'll reach out to this number within 24 hrs